<DOC>
	<DOCNO>NCT01514188</DOCNO>
	<brief_summary>This phase 2b , randomize , open-label , prospective , multicenter study compare treatment INNO 206 doxorubicin subject metastatic , locally advanced , unresectable soft tissue sarcomas previously treat chemotherapy except potentially adjuvant neoadjuvant chemotherapy , evidence tumor recurrence occur least 12 month .</brief_summary>
	<brief_title>Preliminary Efficacy Safety INNO-206 Compared Doxorubicin Advanced Soft Tissue Sarcoma</brief_title>
	<detailed_description>One hundred five subject enrol randomized 2:1 receive either INNO-206 doxorubicin . INNO-206 dosage 350 mg/m2 ( doxorubicin equivalent 260 mg/m2 ) administer 30 minute IVI Day 1 cycle approximately 70 subject . Doxorubicin ( 75 mg/m2 ) administer approximately 35 subject Day 1 cycle . An individual cycle therapy define 3-week ( 21-day ) period . Cycles repeat every 3 week . Multiple cycle may administer subject withdrawn therapy maximum 6 cycle administer . Overall response rate well individual category response ( CR , PR , SD , PD ) determine use RECIST 1.1 . [ 28 ] Time-to-event endpoint , include PFS OS assess use Kaplan Meier method . [ 30 ] Evaluation 4- 6-month progression-free survival also perform . Toxicity ( adverse event ) record use NCI CTCAE , version 4.0 ( publish 28 May 2009 ) .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>Age 1580 year ( US ) , 1880 ( rest world ( ROW ) ) , male female . Adjuvant neoadjuvant chemotherapy ( include doxorubicin ) allow tumor recurrence least 12 month since last measurement , begin end last chemotherapy . Histologically cytologically confirm , locally advanced , unresectable , and/or metastatic soft tissue sarcoma intermediate high grade . Capable provide informed consent comply trial procedure . ECOG performance status 02 . Life expectancy &gt; 12 week . Measurable tumor lesion accord RECIST 1.1 criterion . Women must able become pregnant ( e.g . postmenopausal least 1 year , surgically sterile , practice adequate birth control method ) duration study . ( Adequate contraception include : oral contraception , implanted contraception , intrauterine device implant least 3 month , barrier method conjunction spermicide . ) Women child bear potential must negative serum urine pregnancy test Screening Visit nonlactating . Geographic accessibility site ensures subject able keep studyrelated appointment . Prior chemotherapy unless adjuvant neoadjuvant therapy tumor recurrence least 12 month . Prior exposure &gt; 3 cycle 225 mg/m2 doxorubicin Doxil® . Palliative surgery and/or radiation treatment le 4 week prior Randomization . Exposure investigational agent within 30 day Randomization . Current Stage 1 2 soft tissue sarcoma . Current evidence/diagnosis alveolar soft part sarcoma , chondrosarcoma , rhabdomyosarcoma , osteosarcoma , gastrointestinal stromal tumor ( GIST ) , dermatofibrosarcoma , Ewing 's sarcoma , Kaposi 's sarcoma , mixed mesodermal tumor , clear cell sarcomas unresectable low grade liposarcoma . Central nervous system metastasis History malignancy except cure basal cell carcinoma , superficial bladder cancer carcinoma situ cervix unless document free cancer &gt; 5 year . Laboratory value : Screening serum creatinine &gt; 1.5x upper limit normal ( ULN ) , alanine aminotransferase ( ALT ) &gt; 3 × ULN &gt; 5 × ULN liver metastasis present , total bilirubin &gt; 3 × ULN , absolute neutrophil count &lt; 1,500/mm3 , platelet concentration &lt; 100,000/mm3 , hematocrit level &lt; 25 % female &lt; 27 % male , coagulation test ( prothrombin time [ PT ] , partial thromboplastin time [ PTT ] , International Normalized Ratio [ INR ] ) &gt; 1.5 × ULN , albumin &lt; 2.0 g/dL . Clinically evident congestive heart failure &gt; class II New York Heart Association ( NYHA ) guideline . Current , serious , clinically significant cardiac arrhythmia , define existence absolute arrhythmia ventricular arrhythmia classify Lown III , IV V. Baseline QTc &gt; 470 msec and/or previous history QT prolongation take medication . Concomitant use medication associate high incidence QT prolongation allow . History sign active coronary artery disease without angina pectoris . Serious myocardial dysfunction define scintigraphically ( e.g . MUGA , myocardial scintigram ) ultrasound determine absolute leave ventricular ejection fraction ( LVEF ) &lt; 45 % predict . History HIV infection . Active , clinically significant serious infection require treatment antibiotic , antiviral antifungal . Major surgery within 3 week prior Randomization . Substance abuse condition might interfere subject 's participation study evaluation study result . Any condition unstable could jeopardize subject 's participation study .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>sarcoma</keyword>
	<keyword>soft-tissue sarcoma</keyword>
	<keyword>Metastatic , locally advanced , unresectable soft tissue sarcoma</keyword>
</DOC>